The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the accelerating pace of M&A activity within the biotech sector to drive therapeutic innovation, argenx has announced a definitive agreement to acquire Forte Biosciences. Under the terms, argenx will commence a cash tender offer for all outstanding shares of Forte at $77 per share, valuing the company at approximately $2.2 billion. The acquisition primarily aims to integrate FB102, a promising antibody targeting immunology-related conditions, following successful early-stage clinical trials.
This transaction occurs as major industry players seek to expand their specialized drug portfolios, with the offer price representing a significant premium for Forte Biosciences. Per market data, FBRX shares closed at $54.78 on July 24, 2026, highlighting the substantial value the acquisition offer brings to shareholders. Meanwhile, argenx (ARGX) was priced at $918.22 at the close of July 24, 2026, having reached a day high of $935.88 during that session.
Investors are now monitoring the completion of the cash tender offer and the integration timeline for the new assets, with ARGX at $918.22 and FBRX at $54.78 (close July 24, 2026). According to the economic calendar, there are no immediate upcoming catalysts for these specific instruments; however, focus will remain on the 14D-9 regulatory filings and final merger approvals to assess the long-term financial impact on argenx's cash position.